Pharnext SA (OTCMKTS:PNEXF – Free Report) shares are scheduled to reverse split before the market opens on Monday, September 18th. The 1-5000 reverse split was announced on Monday, September 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 18th. Pharnext Price Performance PNEXF stock opened at […]
Pharnext SA (OTCMKTS:PNEXF – Free Report) shares are scheduled to reverse split on Monday, September 18th. The 1-5000 reverse split was announced on Monday, September 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 18th. Pharnext Price Performance PNEXF stock opened at $400.00 on Thursday. Pharnext […]
PARIS, France, June 14th, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high. | June 14, 2023
PARIS, France, June 8th, 2023, 08:30 am CET - Pharnext SA ( FR001400GUN7 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative
New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on